

**Table SI. Clinical characteristics of psoriatic patients with tuberculin skin test (TST) positivity**

Characteristics	Value
Patients, <i>n</i>	95
Age, years, mean ± SD	52 ± 14
Sex (male), <i>n</i> (%)	53 (56)
Baseline PASI, mean ± SD	24 ± 9
Psoriasis duration, years, mean ± SD	17 ± 13
Psoriatic arthritis, <i>n</i> (%)	30 (32)
Diabetes mellitus, <i>n</i> (%)	31 (33)
Hypertension, <i>n</i> (%)	40 (42)
Body mass index >25, <i>n</i> (%)	61 (64)
Prior treatment with cyclosporine, <i>n</i> (%)	8 (8)
Prior treatment with methotrexate, <i>n</i> (%)	68 (72)
Prior BCG vaccination, <i>n</i> (%)	48 (51)
High TB incidence in country of origin <sup>a</sup> , <i>n</i> (%)	35 (37)
Area of origin, <i>n</i> (%)	
Eastern Europe	16 (17)
Asia	10 (11)
Africa	8 (8)
South America	1 (1)
Chest X-ray suggestive of TB, <i>n</i> (%)	8 (8)
TST-positive (unconfirmed), <i>n</i> (%)	52 (55)
Confirmatory QFT, <i>n</i> (%)	43 (45)
TST+/QTF+, <i>n</i> (%)	4 (4)
TST+/QTF-, <i>n</i> (%)	39 (41)
TST induration size, mean ± SD	12 ± 5 <sup>b</sup>
TST conversion during treatment (% of patients undergoing successive screening), <i>n</i> (%)	17/52 (33)
Prophylaxis, <i>n</i> (%)	56 (59)
Co-treatment with methotrexate, <i>n</i> (%)	17 (18)
Number of biologic agents, mean ± SD	2.3 ± 1.1
Biologic agent used (prevalence), %	
Etanercept	83
Adalimumab	66
Ustekinumab	45
Secukinumab	15
Infliximab	11
Golimumab	2
Efalizumab	2
Alefacept	1
Treatment duration, months, mean ± SD	45 ± 31

<sup>a</sup>Defined as > 40 per 100,000 per year. <sup>b</sup>Out of 56 patients with available data.

PASI: Psoriasis Activity and Severity Index; BCG: Bacillus Calmette-Guerin; TB: tuberculosis; QFT: QuantiFERON TB [assay]; SD: standard deviation; TST: tuberculin skin test.